Abstract:BackgroundThe incidence of cefepime-induced neurotoxicity (CIN) has been previously underestimated, and there have only been sporadic reports from critical neurological settings. The present study aimed to investigate the potential factors associated with disease development, electroencephalography (EEG) sub-classification, and outcome measures.MethodsThe 10-year medical records of patients who underwent EEG between 2007 and 2016 at a tertiary medical center in Taiwan, and developed encephalopathy after cefepime therapy were retrospectively reviewed. Age- and sex-matched controls were included for further analysis. Demographic data, the occurrence of clinical seizures, non-convulsive status epilepticus (NCSE), use of antiepileptic drugs (AEDs), receiving maintenance or urgent hemodialysis, EEG findings, and functional outcomes were analyzed. The Chi-square test and a logistic regression model were applied to survey significant prognostic factors relating to mortality.ResultsA total of 42 CIN patients were identified, including 25 patients from wards and 17 from intensive care units; their mean age was 75.8 ± 11.8 years. Twenty-one patients (50%) had chronic kidney disease, and 18 (43%) had acute kidney injury. Among these patients, 32 (76%) received appropriate cefepime dose adjustment. Three patients had a normal renal function at the time of CIN onset. The logistic regression model suggested that maintenance hemodialysis and longer duration of cefepime use were independently associated with the development of CIN, with odds ratios of 3.8 and 1.2, respectively. NCSE was frequently noted in the CIN patients (64%). Generalized periodic discharge with or without triphasic morphology was the most common EEG pattern (38%), followed by generalized rhythmic delta activity and generalized spike-and-waves. AEDs were administered to 86% of the patients. A total of 17 patients (40%) did not survive to hospital discharge. Adequate cefepime dose adjustment and early cefepime discontinuation led to a better prognosis.ConclusionsCIN was associated with high mortality and morbidity rates. Neurotoxic symptoms could still occur when the cefepime dose was adjusted, or in patients with normal renal function. Patients with maintenance hemodialysis or a longer duration of cefepime therapy tended to develop CIN. Early recognition of abnormal EEG findings allowed for the withdrawal of the offending agent, resulting in clinical improvements and a better prognosis at discharge.

Two cases of ceftriaxone‐induced encephalopathy treated by hemoperfusion in hemodialysis patients

Ceftriaxone-Induced Encephalopathy in a Patient With Chronic Kidney Disease

Intraventricular Plus Systemic Antibiotic Therapy for Treating Polymyxin-Resistant Klebsiella Pneumoniae Ventriculitis: A Case Report

Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature

Clinical, Electroencephalographic Features and Prognostic Factors of Cefepime-Induced Neurotoxicity: A Retrospective Study

Ceftriaxone-induced severe hemolytic anemia, renal calculi, and cholecystolithiasis in a 3-year-old child: a case report and literature review

Severe drug-induced immune hemolysis due to ceftriaxone

Uremic encephalopathy in patients undergoing assisted peritoneal dialysis: a case series and literature review

Cefepime-Induced Neurotoxicity in a 74-Year-Old Woman

Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report

An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone

[Ceftriaxone-induced immune haemolytic anaemia and multi-organ failure]

Severe drug-induced immune hemolytic anemia due to cefmetazole: A case report

Rare but There: Ceftriaxone-Induced Neutropenia in a Patient With a Brain Abscess

Ceftriaxone-Induced Hemolytic Anemia in a Jehovah's Witness

Ceftazidime-Avibactam for the Treatment of Central Nervous System Infection Caused by Pan Drug-Resistant Carbapenem-Resistant Klebsiella Pneumoniae: A Case Report

Acute necrotizing calculous cholecystitis after treatment with ceftriaxone in an elderly patient: a case report

Ceftriaxone alleviates early brain injury after subarachnoid hemorrhage by increasing excitatory amino acid transporter 2 expression via the PI3K/Akt/NF-κB signaling pathway

Danger in plain sight: determining who is at highest risk for cefepime induced neurotoxicity and its associated morbidity and mortality

Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia

Management of patients with renal failure complicated by cerebral oedema